Muscle-Derived Stem Cells for Personalized Drug Testing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The high cost and attrition rate of drug development processes due to unforeseen adverse effects, coupled with the need for personalized medical treatments tailored to a patient's unique genetic background, highlight the need for improved models utilizing stem cells that are accessible and minimally invasive to collect.

Innovation Solution

The use of mammalian pluripotent muscle-derived mesenchymal stem cells obtained through a minimally invasive muscular micro-biopsy, followed by density gradient centrifugation, which are positive for CD105 and negative for CD45, MHCII, and CD29, allowing for the assessment of pharmaceutical compound efficacy and adverse effects without external growth factors, enabling personalized medicine.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If stem cells are collected from bone marrow or adipose tissues, then sufficient quantities of pluripotent stem cells can be obtained, but the collection procedure is invasive and painful

Engineering Contradiction:

Improvequantity of stem cellsVSAvoidinvasiveness of collection

Core Design Contradiction:

Quantity of substanceVSEase of operation

Solution Approach 1:

The patent extracts stem cells from a different, more accessible source (muscle tissue via micro-biopsy) rather than from the traditional invasive sources (bone marrow or adipose tissue). This extraction from an alternative location resolves the contradiction by providing sufficient stem cell quantities through a minimally invasive procedure.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses muscle-derived stem cells as a surrogate or substitute for bone marrow or adipose-derived stem cells. These muscle-derived cells copy the essential pluripotent characteristics and functionality needed for drug testing, eliminating the need to perform invasive collections from traditional sources.

Inventive Principle:

Principle #26Copying

2Productivity

If conventional drug development processes are used, then drug candidates can be evaluated, but high attrition rates occur due to unforeseen adverse effects

Engineering Contradiction:

Improvedrug development efficiencyVSAvoidprediction of adverse effects

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent performs preliminary testing of drug candidates on patient-specific muscle-derived stem cells before clinical administration. This preliminary action identifies potential adverse effects and non-responsive candidates early in the development process, preventing later failures and improving overall drug development reliability.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses the patient's own muscle-derived stem cells to predict their individual response to drug candidates. The patient's cells serve themselves as the testing substrate, providing personalized predictive information about adverse effects and efficacy specific to that patient's genetic background.

Inventive Principle:

Principle #25Self-service

3Adaptability or versatility

If personalized medicine approaches are implemented, then treatment can be tailored to patient's genetic background, but the cost of drug development increases

Engineering Contradiction:

Improvepersonalization of treatmentVSAvoidcost of drug development

Core Design Contradiction:

Adaptability or versatilityVSLoss of energy

Solution Approach 1:

The patent uses relatively inexpensive muscle tissue micro-biopsies and standard cell culture techniques to create personalized test systems. This disposable approach of culturing patient-specific cells for testing purposes provides personalized medicine at lower cost compared to more complex personalized approaches.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent demonstrates that muscle-derived stem cells can serve multiple functions: they can be used for drug efficacy testing, adverse effect prediction, and personalized treatment planning. This multi-functionality reduces overall costs by consolidating multiple personalized medicine needs into a single cell type platform.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method provides a reliable, cost-effective, and minimally invasive approach for evaluating drug efficacy and adverse effects, reducing attrition rates and supporting personalized treatment by using autologous stem cells that can differentiate into various cell types without losing pluripotency, even after multiple freeze-thaw cycles.

Implementation Method 1

mammalian pluripotent muscle-derived mesenchymal stem cells obtained through a minimally invasive muscular micro-biopsy, followed by density gradient centrifugation

Methodology Applied

Scientific EffectDensity gradient centrifugation: Centrifugal Separation

Data Source

PatentEP3609999B1New uses of mammalian muscle-derived stem cells

Publication Date: 2024.06.12 REVATIS SA

AI summary

The present invention relates to a method for assessing the effects of a compound or composition on a mammal, comprising obtaining mammalian pluripotent muscle-derived mesenchymal stem cells or a population thereof, exposing the said stem cells, stem cell population to the relevant compound or composition, and assessing the effects on the said cells. The invention method is a reliable assessment method applicable to drug development, toxicity testing and optimized personalized medicine.